Skip to main content
Equibles
CELU logo

CELU · Celularity Inc

Track CELU — free

Use CELU with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CELU.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.41 -0.03 (-1.74%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged Apr 30, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-K filed Apr 30, 2026
Market Cap
$40.81M
Shares
28.95M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.41 Open$1.45 Day$1.35–1.45 52W close$0.60–2.33 Avg vol 30d8.2M Short int1.9M · 6.6% float · 1.0d Short vol39% DataFeb 2024–Sep 2026 Filing10-K · Apr 30

Raw chart and full-history price indicators begin at the captured split on Feb 29, 2024; bars on opposite sides are not compared.

Up next

Latest filing: 10-K
filed Apr 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$26.55M
Trailing 12 months
Net income (TTM)
−$91.72M
Trailing 12 months
Revenue growth YoY
-77.4%
Year over year
Operating margin
-230.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.9%
Year over year · more shares
Price change (1Y)
-39.5%
Trailing year
Short interest
6.6%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +24%
above
Price vs 50-day avg +49%
above
RSI (14) 55
neutral
MACD trend Negative
52-week position 47%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +103%
trailing
6-month return +16%
trailing
YTD return +27%
this year
Relative strength −2%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.56% of float · ▲ +370.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
39 holders — mid 3-yr range
Squeeze score 57
elevated · 0–100
Fundamentals
Weak
Revenue growth −51%
Y/Y
Gross margin 25%
expanding
EPS growth −36%
Y/Y
Free cash flow $-13.4M
Quant / Vol
risk profile
Very High
Volatility 164%
annualized · 1-yr
Max drawdown −74%
past year
ATR 16.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+24% Bullish
Price vs 50-day avg
+49% Bullish
RSI (14)
55 Neutral
MACD trend
Negative Bearish
52-week position
47% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.56% of float · ▲ +370.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
39 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 47% Range high $2
vs 200-day avg +24% vs 50-day avg +49%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CELU
Celularity Inc
this stock
$40.81M +27.0% -51.0% — 6.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
39
% held
7.7%
Net QoQ
+47.3K sh
Top holder
C V STARR & CO INC
Held Float
View
Held by Funds
Fund positions
8
View
Short & Settlement
Short Interest Rising
Shares short
1.9M
Days to cover
1.0d
Change
+1.5M sh
View
Short Volume
Short vol %
39%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
55
Value
$37
As of
Aug 7, 2026
View
Off-Exchange
Off-exchange %
52.5%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$26.6M
Net income (FY)
$-91.7M
EPS diluted
$-3.59
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 7, 2026
This year
12
View
Exempt Offerings
Offering
$6.7M
Filed
Nov 3, 2025
View

Performance

Raw-price comparisons begin at the captured split on Feb 29, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
CELU -23.0% +102.9% +15.6% -23.8% +27.0%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -21.8% +104.6% -2.3% -23.4% +15.0%
Key facts CIK 1752828 CUSIP 151190204 13F (30d) 7 filings 7 filers Visit website Investor relations